Voices
What’s Next for Antibody-Drug Conjugates? – SITC
SITC/LinkedIn

What’s Next for Antibody-Drug Conjugates? – SITC

Society for Immunotherapy of Cancer (SITC), shared on LinkedIn:

“What’s next for antibody-drug conjugates? Join the expert panel in Session III: Novel Modality – Antibody-drug Conjugates at the 2026 SITC EU Immuno-Oncology Drug Development Summit and hear where the field is headed.

Register today.”

Other articles about Immunotherapy on OncoDaily.

2026 SITC EU Immuno-Oncology Drug Development Summit ADCs Antibody drug conjugates cancer cancer immunotherapy drug development immuno-oncology OncoDaily Oncology oncology drug development SITC Society for Immunotherapy of Cancer Society for Immunotherapy of Cancer (SITC)